ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 110 filers reported holding ARBUTUS BIOPHARMA CORP in Q2 2022. The put-call ratio across all filers is 0.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $341,501 | -10.5% | 168,232 | +1.5% | 0.00% | – |
| Q2 2023 | $381,379 | +79024.3% | 165,817 | +4.2% | 0.00% | -100.0% |
| Q1 2023 | $482 | +38.5% | 159,127 | +6.4% | 0.00% | – |
| Q4 2022 | $348 | -99.9% | 149,535 | +4.7% | 0.00% | – |
| Q3 2022 | $273,000 | -25.4% | 142,840 | +5.9% | 0.00% | -100.0% |
| Q2 2022 | $366,000 | +18.4% | 134,924 | +30.0% | 0.00% | – |
| Q1 2022 | $309,000 | -12.2% | 103,778 | +14.6% | 0.00% | – |
| Q4 2021 | $352,000 | -9.3% | 90,535 | +0.1% | 0.00% | -100.0% |
| Q3 2021 | $388,000 | +45.9% | 90,464 | +2.9% | 0.00% | – |
| Q2 2021 | $266,000 | +52.9% | 87,918 | +80.9% | 0.00% | – |
| Q1 2019 | $174,000 | -7.4% | 48,597 | -0.9% | 0.00% | – |
| Q4 2018 | $188,000 | -40.9% | 49,032 | +45.9% | 0.00% | -100.0% |
| Q3 2018 | $318,000 | +30.9% | 33,616 | +0.8% | 0.00% | – |
| Q2 2018 | $243,000 | – | 33,356 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 260,000 | $866,000 | 0.34% |
| RTW INVESTMENTS, LP | 5,978,355 | $19,908,000 | 0.31% |
| GSA CAPITAL PARTNERS LLP | 309,839 | $1,032,000 | 0.17% |
| QCM Cayman, Ltd. | 12,728 | $42,000 | 0.13% |
| COWEN AND COMPANY, LLC | 486,717 | $1,621,000 | 0.11% |
| Hudson Bay Capital Management LP | 1,400,000 | $4,662,000 | 0.06% |
| Kerrisdale Advisers, LLC | 208,150 | $693,000 | 0.05% |
| Secure Asset Management, LLC | 10,000 | $33,000 | 0.02% |
| PDT Partners, LLC | 72,500 | $241,000 | 0.02% |
| Point72 Asset Management, L.P. | 1,037,700 | $3,456,000 | 0.02% |